# ENDRA Life Sciences Inc.: Form 8-K, filed Mar 25, 2026

- Company: [ENDRA Life Sciences Inc.](/companies/ndra.md) (CIK 1681682)
- Form: 8-K
- Filed: 2026-03-25
- Accepted by EDGAR: Mar 25, 2026, 09:21 ET
- Period: 2026-03-19
- Accession: 0001213900-26-033878
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1681682/000121390026033878/ea0283331-8k_endra.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1681682/000121390026033878/

## Items reported

- Item 2.05: Exit or disposal costs
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1681682/000121390026033878/ea0283331-8k_endra.htm

Filed Mar 25, 2026.
Source: SEC EDGAR, the filing index for accession 0001213900-26-033878. Last ingested by Listed: Nov 10, 2026, 17:03 ET. No prices; not investment advice.
